Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, glucagon (Baqsimi®) cannot be endorsed for use within NHS Wales for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus. This product is currently not marketed in the UK. |
||
|
||
Medicine details |
||
| Medicine name | glucagon (Baqsimi®) | |
| Formulation | 3 mg nasal powder | |
| Reference number | 3008 | |
| Indication | Treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus |
|
| Company | Eli Lilly & Co Ltd | |
| BNF chapter | Endocrine system | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 04/08/2020 | |